Di Shan (迪善)迪善
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 沈阳兴齐眼药股份有限公司Chinese legal name: 沈阳兴齐眼药股份有限公司
主要成分Active Ingredients
- 阿托品Atuo Pin
药物知识说明
阿托品是一种在国家药监局注册认定的药品。该药品含有阿托品-a0d8e13e等成分。
该药品关联的活性成分包括：阿托品Atuo Pin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：沈阳兴齐眼药股份有限公司Chinese legal name: 沈阳兴齐眼药股份有限公司。
您可以探索含有相同成分的其他药品：阿托品-a0d8e13e成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 迪善) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 阿托品Atuo Pin.
Manufacturers recorded for this product: 沈阳兴齐眼药股份有限公司Chinese legal name: 沈阳兴齐眼药股份有限公司.
Explore other medicines containing the same ingredient: 阿托品 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 迪善Recorded Chinese name: 迪善
- 规格Specification: 2.5g：25mg2.5 g:25 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 沈阳兴齐眼药股份有限公司Chinese legal name: 沈阳兴齐眼药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20052295
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20052295
Manufacturer
Chinese legal name: 沈阳兴齐眼药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20052295
生产企业
沈阳兴齐眼药股份有限公司(国产)
适应症
虹膜睫状体炎、检查眼底前的散瞳、验光配镜屈光度检查前的散瞳。
用法用量
一次1滴，滴于结膜囊内，一天3次。或遵医嘱。
不良反应
1、眼部用药后可能产生皮肤、黏膜干燥、发热、面部潮红，心动过速等现象。|2、少数病人眼睑出现发痒、红肿、结膜充血等过敏现象，应立即停药。
禁忌
青光眼及前列腺肥大者禁用。
注意事项
1.阿托品类扩瞳药对正常眼压无明显影响，但对眼压异常或窄角、浅前房眼患者，应用后可使眼压明显升高而有激发青光眼急性发作的危险。故对这类病例和40岁以上的病人不应用阿托品滴眼。|2.本品应在医师知道下使用。|3.用药时管嘴勿接触眼部，以防污染药品。|4.当药品性状发生改变时禁止使用。|5.滴眼后用手指压迫泪囊部1-2分钟，（见说明书下面图示）减少药液的全身吸收。|6.本品系外用药品，严禁口服。|7.开封后最多可使用四周。|8.请妥为保存，放置儿童触摸不到的地方，避免儿童误食中毒。
贮藏
遮光，密闭，在凉暗处保存。
规格
2.5g：25mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.